The patent application entitled, Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders, claims methods for treating pseudobulbar affect or emotional lability using low-dose quinidine formulations of Nuedexta.
The new patent covering Nuedexta, a dual sigma-1 and NMDA receptor modulator, will expire on 17 July 2023.
Avanir senior vice president and chief business officer Greg Flesher said, "This additional layer of intellectual property protects our growing PBA business in the United States while we continue to explore additional clinical uses for NUEDEXTA."
Nuedexta is a dual sigma-1 and NMDA receptor modulator that is approved for the treatment of pseudobulbar affect (PBA), and is in clinical development for central neuropathic pain in patients with multiple sclerosis and agitation in patients with Alzheimer’s disease.